Article Sidebar
Article Details
Issue
Section
Articles
Authors submitting articles to The Annals of African Surgery do so on the understanding that if accepted, they will retain the copyright and allow the journal to publish and archive the article under the CC BY (Creative Commons Attribution License) 4.0 International. See details on the Creative commons website. All authors will be required to sign an Author Agreement form detailing the agreement with the journal prior to the article being published. Download the form here
This work is licensed under the Creative Commons Attribution 4.0 International License.
Main Article Content
Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
Abstract
Background
The incidence of benign prostatic hyperplasia peaks 80% in old age. Bothersome symptoms and progression to acute urinary retention and need for surgery are important concerns. Apha blockers and 5 alpha reductase inhibitors address these to variable extents. This article reviews the current place of medical therapy in the treatment of BPH, with a focus on combination therapy.
Data Source
A medline literature search was performed to identify original studies including global multi-center trials and reviews on the subject.
Conclusion
BPH symptom reduction and shrinkage of prostate size by the use of a combination of alpha adrenergic uroselective blocker (Tamsulosin) and 5 alpha iso-enzyme inhibitor (Dutasteride) is a first option of therapy in the management of BPH especially in those cases that are surgical risks with the category of mild to moderate prostate symptom scores.
The Annals of African Surgery, Volume 6, 2010
The incidence of benign prostatic hyperplasia peaks 80% in old age. Bothersome symptoms and progression to acute urinary retention and need for surgery are important concerns. Apha blockers and 5 alpha reductase inhibitors address these to variable extents. This article reviews the current place of medical therapy in the treatment of BPH, with a focus on combination therapy.
Data Source
A medline literature search was performed to identify original studies including global multi-center trials and reviews on the subject.
Conclusion
BPH symptom reduction and shrinkage of prostate size by the use of a combination of alpha adrenergic uroselective blocker (Tamsulosin) and 5 alpha iso-enzyme inhibitor (Dutasteride) is a first option of therapy in the management of BPH especially in those cases that are surgical risks with the category of mild to moderate prostate symptom scores.
The Annals of African Surgery, Volume 6, 2010
